Healthcare Services

Adult Malignant Glioma Therapeutics Market Global Report 2026 Market Growth Expected to Reach $3.94 Billion by 2030 with 9.9% CAGR

March 27, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Adult Malignant Glioma Therapeutics Market Expected To Change Between 2026 And 2030?

The adult malignant glioma therapeutics market has experienced robust expansion in recent times. This market is projected to expand from $2.47 billion in 2025 to $2.7 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.1%. Several factors contributed to its historical growth, including the scarcity of effective treatments for malignant gliomas, the consistent application of conventional chemotherapy and radiotherapy, an increasing incidence of adult brain tumors, the expansion of hospital-based oncology services, and a heightened understanding of the necessity for glioma therapies.

The adult malignant glioma therapeutics market size is projected to experience significant growth over the next few years. It is forecast to expand to $3.94 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.9%. This expansion during the forecast period is primarily driven by the development of targeted molecular therapies, an increase in clinical trials for new glioma treatments, growing investment in precision oncology, rising collaborations between biotech and healthcare providers, and the adoption of advanced radiotherapy and combination therapy techniques. Prominent trends anticipated in this period include the continued development of targeted glioma therapies, a rising preference for combination treatment approaches, the broadening of experimental and personalized therapies, a greater focus on improving patient quality of life, and the increased utilization of advanced radiotherapy techniques.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13178&type=smp

Which Major Factors Are Driving The Expansion Of The Adult Malignant Glioma Therapeutics Market?

The future expansion of the adult malignant glioma therapeutics market is anticipated to be driven by government financial backing for brain cancer research. This type of funding denotes monetary assistance extended by governmental bodies—federal, state, or local—to a range of organizations, ventures, projects, programs, or individuals. Such government investment in brain cancer research proves beneficial for adult malignant glioma therapeutics, facilitating the creation of innovative treatments, personalized drug development, approaches targeting pyrimidine synthesis, and the approval of orphan drugs. A notable illustration is the Australian Department of Health and Aged Care, an Australian government authority, which launched the Australian Brain Cancer Mission in June 2023, allocating $136.66 million to bolster brain cancer research. This particular initiative seeks to significantly enhance the survival rates and consequently elevate the life quality for individuals suffering from brain cancer, specifically anaplastic astrocytoma. Consequently, financial support from governments for brain cancer research acts as a key catalyst for the adult malignant glioma therapeutics market.

How Is The Adult Malignant Glioma Therapeutics Market Structured Across Different Segments?

The adult malignant glioma therapeutics market covered in this report is segmented –

1) By Type Of Disease: Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Other Types

2) By Therapy: Chemotherapy, Targeted Therapy, Radiotherapy, Other Therapies

3) By End-User: Hospitals, Specialty Clinics, Cancer And Radiation Therapy Centers, Other End Users

Subsegments:

1) By Glioblastoma Multiforme: Standard Treatments, Experimental Therapies

2) By Anaplastic Astrocytoma: Chemotherapy Options, Targeted Therapies

3) By Anaplastic Oligodendroglioma: Radiation Therapy, Combination Therapies

4) By Anaplastic Oligoastrocytoma: Surgical Interventions, Adjuvant Therapies

5) By Other Types: Rare Gliomas, Emerging Therapies

Which Trends Are Shaping The Future Of The Adult Malignant Glioma Therapeutics Market?

Leading companies within the adult malignant glioma therapeutics market are innovating products like small molecule targeted degraders to deliver dependable customer services. A small-molecule targeted degrader functions as a drug utilizing small molecules to prompt the degradation of specific proteins by targeting both a protein of interest (POI) and an E3 ubiquitin ligase. For example, in February 2023, Beactica Therapeutics AB, a precision oncology company from Sweden, secured orphan drug designation approval from the U.S. Food and Drug Administration (FDA) for BEA-17, intended for treating glioblastoma (GBM). BEA-17 is a small-molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST, which are implicated in the development of various cancers, including GBM. This agent operates by degrading LSD1 and CoREST, resulting in the reactivation of tumor suppressor genes and suppression of cancer cell growth.

Which Major Players Dominate The Adult Malignant Glioma Therapeutics Market?

Major companies operating in the adult malignant glioma therapeutics market are Johnson & Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche Ltd., Allergan plc, AbbVie Inc., Novartis AG, Bayer AG, Merck & Co Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., GT Medical Technologies Inc., Lupin Limited, Mylan NV, Sanofi SA, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Genentech Inc., Amneal Pharmaceuticals LLC, Emcure Pharmaceuticals Limited, Novocure Ltd., Arbour Pharmaceuticals LLC, Basilea Pharmaceuticals Ltd.

Read the full adult malignant glioma therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/adult-malignant-glioma-therapeutics-global-market-report

Which Region Currently Holds The Largest Share Of The Adult Malignant Glioma Therapeutics Market?

North America was the largest region in the adult malignant glioma therapeutics market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adult malignant glioma therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Adult Malignant Glioma Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=13178&type=smp

Browse Through More Reports Similar to the Global Adult Malignant Glioma Therapeutics Market 2026, By The Business Research Company

glioma treatment global market report

https://www.thebusinessresearchcompany.com/report/glioma-treatment-global-market-report

pontine glioma drugs global market report

https://www.thebusinessresearchcompany.com/report/pontine-glioma-drugs-global-market-report

Brain Tumor Drugs Global Market Report

https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795